Petra J Woestenberg1, Audrey J King2, Marianne A B van der Sande3, Robine Donken4, Suzan Leussink5, Fiona R M van der Klis6, Christian J P A Hoebe7, Johannes A Bogaards8, Birgit H B van Benthem9. 1. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands; School of Public Health and Primary Care, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Electronic address: petra.woestenberg@rivm.nl. 2. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: audrey.king@rivm.nl. 3. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands; Julius Center, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Electronic address: marianne.van.der.sande@rivm.nl. 4. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands; Department of Pathology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: robine.donken@rivm.nl. 5. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: suzan.leussink@rivm.nl. 6. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: fiona.van.der.klis@rivm.nl. 7. School of Public Health and Primary Care, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands; Department of Sexual Health, Infectious Diseases and Environment, South Limburg Public Health Service, P.O. Box 2022, 6160 HA Geleen, The Netherlands. Electronic address: christian.hoebe@ggdzl.nl. 8. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: hans.bogaards@rivm.nl. 9. Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: birgit.van.benthem@rivm.nl.
Abstract
OBJECTIVES: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands. METHODS: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior. RESULTS: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not change these results. CONCLUSIONS: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW.
OBJECTIVES: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands. METHODS: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior. RESULTS: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not change these results. CONCLUSIONS: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW.
Authors: Petra J Woestenberg; Audrey J King; Birgit H B van Benthem; Robine Donken; Suzan Leussink; Fiona R M van der Klis; Hester E de Melker; Marianne A B van der Sande; Christian J P A Hoebe; Johannes A Bogaards Journal: J Infect Dis Date: 2018-01-04 Impact factor: 5.226
Authors: Emilien Jeannot; Manuella Viviano; Charlotte de Pree; Mona Amadane; Emmanuel Kabengele; Pierre Vassilakos; Patrick Petignat Journal: Int J Environ Res Public Health Date: 2018-07-09 Impact factor: 3.390
Authors: Johannes A Bogaards; Pascal van der Weele; Petra J Woestenberg; Birgit H B van Benthem; Audrey J King Journal: J Infect Dis Date: 2019-08-30 Impact factor: 5.226
Authors: Pam Sonnenberg; Clare Tanton; David Mesher; Eleanor King; Simon Beddows; Nigel Field; Catherine H Mercer; Kate Soldan; Anne M Johnson Journal: Sex Transm Infect Date: 2019-02-05 Impact factor: 3.519
Authors: Ángela María Ruiz-Sternberg; Edson D Moreira; Jaime A Restrepo; Eduardo Lazcano-Ponce; Robinson Cabello; Arnaldo Silva; Rosires Andrade; Francisco Revollo; Santos Uscanga; Alejandro Victoria; Ana María Guevara; Joaquín Luna; Manuel Plata; Claudia Nossa Dominguez; Edison Fedrizzi; Eugenio Suarez; Julio C Reina; Misoo C Ellison; Erin Moeller; Michael Ritter; Christine Shields; Miguel Cashat; Gonzalo Perez; Alain Luxembourg Journal: Papillomavirus Res Date: 2017-12-19